Literature DB >> 1388140

Influence of cefodizime on the reagibility of human leukocytes.

M Limbert1, H Müllner, P M Shah.   

Abstract

Cefodizime was evaluated for its effect on a number of parameters of leukocyte function in humans. Four healthy volunteers received 2 g i.v. b.i.d. for seven days. Leukocyte activity was measured before, during and after treatment. Using opsonized zymosan as a stimulant, no effect on the respiratory burst of granulocytes was observed. It was found, however, that the lymphocytes in three of the four subjects showed significantly more marked proliferation rates in the mixed lymphocyte reaction after administration of cefodizime than at baseline. The stimulation indices subsequently returned to normal. This pilot study therefore demonstrated that cefodizime has biological response modifying properties in healthy humans.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1388140     DOI: 10.1007/bf01709952

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  Isolation of lymphocytes, granulocytes and macrophages.

Authors:  A Bøyum
Journal:  Scand J Immunol       Date:  1976-06       Impact factor: 3.487

2.  In vitro and ex vivo enhancement of nonspecific phagocytosis by cefodizime.

Authors:  A Fietta; C Bersani; R Bertoletti; F M Grassi; G G Grassi
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

3.  Cefodizime, an aminothiazolylcephalosporin. I. In vitro activity.

Authors:  M Limbert; N Klesel; K Seeger; G Seibert; I Winkler; E Schrinner
Journal:  J Antibiot (Tokyo)       Date:  1984-08       Impact factor: 2.649

4.  In vivo antibacterial activity of cefodizime, a new cephalosporin antibiotic.

Authors:  K Kasai; A Tsuji; S Miyazaki; S Goto; K Fujimoto; S Masuyoshi; S Arai
Journal:  Jpn J Antibiot       Date:  1984-07

5.  Cefodizime, an aminothiazolylcephalosporin. II. Comparative studies on the pharmacokinetic behavior in laboratory animals.

Authors:  N Klesel; M Limbert; K Seeger; G Seibert; I Winkler; E Schrinner
Journal:  J Antibiot (Tokyo)       Date:  1984-08       Impact factor: 2.649

6.  Cefodizime, an aminothiazolyl cephalosporin. IV. Influence on the immune system.

Authors:  M Limbert; R R Bartlett; G Dickneite; N Klesel; H U Schorlemmer; G Seibert; I Winkler; E Schrinner
Journal:  J Antibiot (Tokyo)       Date:  1984-12       Impact factor: 2.649

7.  Mechanisms of non-opsonized zymosan-induced and luminol-enhanced chemiluminescence in whole blood and isolated phagocytes.

Authors:  J Lindena; H Burkhardt; A Dwenger
Journal:  J Clin Chem Clin Biochem       Date:  1987-11

8.  Cefodizime: a new cephalosporin with apparent immune-stimulating properties in chronic renal failure.

Authors:  R Vanholder; N Van Landschoot; E Dagrosa; S Ringoir
Journal:  Nephrol Dial Transplant       Date:  1988       Impact factor: 5.992

Review 9.  Antimicrobial drugs, microorganisms, and phagocytes.

Authors:  P J van den Broek
Journal:  Rev Infect Dis       Date:  1989 Mar-Apr
  9 in total
  5 in total

1.  In vitro effect of cefodizime, imipenem/cilastatin and co-trimoxazole on dexamethasone and cyclosporin A depressed phagocytosis.

Authors:  A Dhondt; R Vanholder; M A Waterloos; G Glorieux; R De Smet; S Ringoir
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

Review 2.  Immunomodulating effects of antibiotics: literature review.

Authors:  B Van Vlem; R Vanholder; P De Paepe; D Vogelaers; S Ringoir
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

3.  Cefodizime host-defence enhancement: considerations of dose-response relationships in healthy volunteers.

Authors:  G Gialdroni Grassi; P M Shah
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 4.  Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

5.  Reduction by cefodizime of the pulmonary inflammatory response induced by heat-killed Streptococcus pneumoniae in mice.

Authors:  Y Bergeron; N Ouellet; A M Deslauriers; M Simard; M Olivier; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.